Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NY\iemVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP NUjQenhtOjV7NkCyPFI>
KellyCis83 NF;UdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMUdihKnDueLCiUCuNFIh|ryP M4rZRVI2QTZyMkiy
SK-N-AS NVzpcG5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP NY\iVJFIOjV7NkCyPFI>
SK-N-ASCis24 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e5TmlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= NXzNc2NCOjV7NkCyPFI>
U87 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rHRlAuPTBizszN MV[0PEBp NE\2OlJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= M3zCV|I2PzVyMkez
HCT116 NX71WoZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[zNmUxNjVvMj61JO69VQ>? NFXEOG41QMLiaNMg MXvJR|UxRTFwN{RCpOKyyqByLkKxxsDPxE1? M4m4VlI2PzR4N{[z
HT-29 NYrKOWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLUb4NvOC53LUKuOUDPxE1? M1;GWFQ5yqCqwrC= M2HHN2lEPTB;Nz6yxsDDucLiMT6wOOKh|ryP NVfsR5lvOjV5NE[3OlM>
Caco2 M2XYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSwMlUuOi53IN88US=> NIm3Sms1QMLiaNMg M{PPN2lEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= NHz0bZIzPTd2Nke2Ny=>
COLO 205 MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\2d|AvPS1{LkWg{txO NFHFPVE1QMLiaNMg M4XUd2lEPTB;MT62NeKhyrIEoECuNFLDqM7:TR?= NVfPRmZFOjV5NE[3OlM>
SW480 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTEUFB1OC53LUKuOUDPxE1? NHPTTIU1QMLiaNMg MX\JR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? Moq4NlU4PDZ5NkO=
HEK293T Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXyV|kyNTVizszN M3TmelQ5yqCqwrC= Ml;nTWM2OD1{LkSyxsDDucLiMD6wOeKh|ryP M1PXfVI2PzR4N{[z
Hep3B  M2nnRWZ2dmO2aX;uJGF{e2G7 M{XXeVExKM7:TR?= NILmTo41QMLiaNMg NUnRe4ZLemWmdXPld{B1cGViZX7oZY5kcW6pIHXm[oVkfCCxZjDCUXAuPg>? NIDvXo0zPTZ|M{W2OC=>
Hep3B  MlX5SpVv[3Srb36gRZN{[Xl? NU\VdpM5OC5zLUGwJO69VQ>? NEG5TGEzPCCq MoDHd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D MVmyOVY{OzV4NB?=
HEK293 NFrSW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTdwMUVCpOKyyqByLkO2xsDPxE1? NUf2fnVXOjV4MEOxNlI>
DU145 NF7uSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwMklCpOKyyqByLkC0xsDPxE1? NF36doszPTZyM{GyNi=>
HCT15 NES5UmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDkTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP M1vrV|I2PjB|MUKy
T47D M{f0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjIXW9IUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN NFK4N4czPTZyM{GyNi=>
SMMC-7721 NVnISYNZTnWwY4Tpc44hSXO|YYm= M{XFRlQxKM7:TR?= Mlm1OFghcA>? MlzxSG1UVw>? M13NXIlv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v NUnZcGY2OjV3NESzOlE>
MDA-MB-231 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv2O|LDqGh? M4S3cGlEPTB;MkGuNuKhyrIEoESuNuKh|ryP MnfpNlU1QDZ{MUm=
MCF-7 M1e4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi3NuKhcA>? NYnhcm51UUN3ME2xNE46yqEEsdMgNk4yyqEQvF2= NXToWYprOjV2OE[yNVk>
Jurkat M3q1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojlO|LDqGh? NETrO2RKSzVyPUGuNuKhyrIEoEGuOeKh|ryP NUX2RpNtOjV2OE[yNVk>
HeLa NI[0SotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW3NuKhcA>? MVvJR|UxRTNwOdMgxtHDqDJwM9Mg{txO NW\qRXh3OjV2OE[yNVk>
MCF7  M1r3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW1MVExOCEQvF2= NVfNS3lqPyCm MoTybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF;JWWozPTR5Mk[xPS=>
K562 NXXRUFloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vnSlczyqCq MonrTWM2OD1yLkK5xsDPxE1? MmS4NlUzQDJ4NUO=
K/VP.5 M2\mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnnfXg4OsLiaB?= NYe2S212UUN3ME20MlnDqM7:TR?= MnfVNlUzQDJ4NUO=
SH-EP  MYTGeY5kfGmxbjDBd5NigQ>? MonDNlDDqM7:Zz;tcC=> Mn;yNlTDqGh? NFvEXGFqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\W6mb3flco92eyCGRWDQ MnH3NlUzPjF7OEG=
SCC25 NEW2bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DZTlI1yqCq NWXaXJBKUUN3ME20N{4{yqEEsdMgNU4yOsLizszN MVKyOVIzODd{OR?=
CAL27 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrPdnQzPMLiaB?= NVP5RWw5UUN3ME21Nk4yyqEEsdMgNU4xQcLizszN MYmyOVIzODd{OR?=
FaDu NWfEUJBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPQR4kzPMLiaB?= NWrmfnF1UUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> M1j6fVI2OjJyN{K5
SCC25 M1PqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XydlQ5yqCq MXLJR|UxRTJyLki2xsDDucLiMT6wO:Kh|ryP M3TacVI2OjJyN{K5
CAL27 M4nLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHyOFjDqGh? MUHJR|UxRTF6LkK0xsDDucLiMT6xOeKh|ryP M3HofFI2OjJyN{K5
FaDu MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnYSFUxPDkEoHi= NF3i[HZKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= MnHLNlUzOjB5Mkm=
SCC25 M2n6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nTe|czyqCq Mne1TWM2OD16LkSxxsDDucLiMT6xNeKh|ryP MnPyNlUzOjB5Mkm=
CAL27 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHqdXpyPzMEoHi= MmfsTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP NWnCU|hCOjV{MkC3Nlk>
FaDu NEHu[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH3S3U4OsLiaB?= MkX2TWM2OD13LkCyxsDDucLiMT6xOeKh|ryP NVzG[WNmOjV{MkC3Nlk>
MCF-7 NVXRSYdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[1S25CPDkEoHlCpC=> MWXEUXNQ MonPTWM2OD15LkNCpOKyyqByLklCpO69VQ>? NHn3XWszPTJzNkO3PC=>
T-47D NXS1fohkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG0POKhcMLi NEnNbHlFVVOR NGq2b29KSzVyPUeuO:KhyrIEoECuO:Kh|ryP MW[yOVIyPjN5OB?=
MDA-MB-231 NEPVSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPYOFjDqGkEoB?= NIXtWoNFVVOR NFHTZ5lKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= MXmyOVIyPjN5OB?=
DU145 NGT4RVBCeG:ydH;zbZMhSXO|YYm= NWnxU3lqOTBvMUCwJO69VQ>? MnuxPEBp Mo[3SG1UVw>? Mo\EbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MXSyOVE1QTZ6MR?=
DU145 stem-like NYixN|kxSXCxcITvd4l{KEG|c3H5 MV2xNE0yODBizszN NYT1PYtSQCCq NVn5N5FyTE2VTx?= MWfpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnTDNlUyPDl4OEG=
DU145 MWnGeY5kfGmxbjDBd5NigQ>? MYexNE0yODBizszN M4PKdFIhcA>? NUjKdpJMTE2VTx?= NF3Rcm1qdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGDLPIczPTF2OU[4NS=>
DU145 stem-like MY\GeY5kfGmxbjDBd5NigQ>? NVToVXpbOTBvMUCwJO69VQ>? MkPzNkBp NVHaOWQyTE2VTx?= M2PnbYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHzpfYgzPTF2OU[4NS=>
UW228-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH25NIMxNjBzLUOwNEDPxE1? MXm0PEBp MX7EUXNQ MlrUTWM2OD1yLkm5xsDPxE1? NVm4U3ZlOjVzMUmxPFU>
NSCs NX;VSHd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2wMlAyNTNyMDFOwG0> NWTt[Xh2PDhiaB?= MnzQSG1UVw>? MULJR|UxRTBwMz2zxsDPxE1? MljXNlUyOTlzOEW=
MKL-1  MV7GeY5kfGmxbjDBd5NigQ>? NVLpdnhJOTBvMUCwNEBvVQ>? MlTzOEBl NVn3cFFYcW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= NYP5eG9sOjVzMU[3OVQ>
MCF7 EV NHHD[GJHfW6ldHnvckBCe3OjeR?= NFLiOJgyOC1zMECg{txO M1HpUlLjiImq MV\pcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> NHOwR5UzPTB6OEKwNy=>
MCF 7BMI1 MoXvSpVv[3Srb36gRZN{[Xl? NWm3XmtROTBvMUCwJO69VQ>? MYOy5qCKcA>? M3q4dolv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ NF;3SFEzPTB6OEKwNy=>
MCF7 EV M3mxZmZ2dmO2aX;uJGF{e2G7 M2LUTFExNTFyMDFOwG0> NEjOTXQz6oDLaB?= NILUWWFGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> NGPUeZQzPTB6OEKwNy=>
MCF7 BMI1 NWSxc|JCTnWwY4Tpc44hSXO|YYm= MVixNE0yODBizszN NIO3Rmsz6oDLaB?= MmizSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u M{mwXFI2ODh6MkCz
HepG2 NWfh[WR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPkSG1UV8Li NWDqVlhXUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> MnOxNlUxPzh|MUG=
MOLT-3 NFSzSmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnnSG1UV8Li M4G4R2lEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN MnjWNlUxPzh|MUG=
HT1080 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGxMVExOCEQvF2= MWS0M|I1NzR6IHi= M4GxdWROW00EoB?= NGXN[2tqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NFr6eWMzPTB5OEC2OC=>
HT1080 NXnBZ5AzTnWwY4Tpc44hSXO|YYm= NITqSWYxNjByMEGtNVAxKM7:TR?= NGfH[YwyNTJ2IHi= MmH1SG1UV8Li NIPZWHFqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MmS3NlUxPzhyNkS=
HT1080 NFzFNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrSNE4xODBzLUGwNEDPxE1? NFz3WWMzPCCq MXvEUXNQyqB? MX;jZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| MYKyOVA4QDB4NB?=
HD-MY-Z MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm3NnRVOjRxNEivO|IhcA>? NGjjdppKSzVy78{eNVAxKM7:TR?= MkGxNlUxPDh{M{[=
DOHH-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLI[JR{OjRiaB?= MnjYTWM2OO,:nkGwNEDPxE1? NIPpWWYzPTB2OEKzOi=>
DOHH-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{THNVQ5KGh? NHLTeZJKSzVyPUG5MlnDqM7:TR?= M1rLOVI2ODR6MkO2
DOHH-2 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\yTYE4OiCq M2rD[GlEPTB;NdMg{txO MYWyOVA1QDJ|Nh?=
REH NYDORpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXBdXgzPCCq NELncW9KSzVyPUCuNFI4yqEQvF2= NELMN5AzPTB2OEKzOi=>
REH NHmzS4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[0PEBp M4G3d2lEPTB;MD6wNVTDqM7:TR?= Mo\nNlUxPDh{M{[=
REH M3PPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HqW|czKGh? MYrJR|UxRTBwMEG1xsDPxE1? Ml;0NlUxPDh{M{[=
HH M4rGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrVNlQhcA>? M3jWSGlEPTB;MUC0MlfDqM7:TR?= NH\R[W4zPTB2OEKzOi=>
HH Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH32eXE1QCCq NEfCVIxKSzVyPUS4MlbDqM7:TR?= MlXmNlUxPDh{M{[=
HH NF23dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHmxPYI4OiCq MnvpTWM2OD1zND63xsDPxE1? M2PPVFI2ODR6MkO2
HuT-78 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHs[mVGOjRiaB?= M2XiWWlEPTB;OT6zxsDPxE1? NFXTS2MzPTB2OEKzOi=>
HuT-78 M1rxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO1OFghcA>? MmPGTWM2OD12LkRCpO69VQ>? MUeyOVA1QDJ|Nh?=
HuT-78 MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi3NkBp NYDG[IlsUUN3ME20MlLDqM7:TR?= NELNVXgzPTB2OEKzOi=>
OPM-2 M1jXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;6cWEzPCCq MnrkTWM2OD1{ND6xxsDPxE1? M2SxUlI2ODR6MkO2
OPM-2 NEDEcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT3OFghcA>? M3fQXWlEPTB;NNMg{txO M1fEOFI2ODR6MkO2
OPM-2 M1PK[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTxT3hIPzJiaB?= MWfJR|UxRTFwM9Mg{txO M3u1NlI2ODR6MkO2
RPMI-8226 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvOSGQzPCCq M1H0OGlEPTB;MUC2MlbDqM7:TR?= NFHZTZAzPTB2OEKzOi=>
RPMI-8226 NVG0WmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHieYxEPDhiaB?= M2jK[mlEPTB;OUGuNeKh|ryP M2LvT|I2ODR6MkO2
RPMI-8226 NVXhPItwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVq3NkBp MlqwTWM2OD1zND65xsDPxE1? NHzER2czPTB2OEKzOi=>
U-266 NXnRR4E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWyOEBp MorXTWM2OD16Nj6yxsDPxE1? MWiyOVA1QDJ|Nh?=
U-266 M4LHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PPOVQ5KGh? Ml3hTWM2OD14OD60xsDPxE1? M{K5RlI2ODR6MkO2
U-266 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfkO|IhcA>? NXuyPW94UUN3ME2yO{41yqEQvF2= NVvt[ml4OjVyNEiyN|Y>
Kelly NFjVR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTxdZJJOC1zMDFOwG0> NF3qOo04OsLiaB?= M2HxWGlEPTB;MT61NVjDqM7:TR?= M1z0V|I2ODB6OUCw
SH-SY5Y  Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLrNE0yOCEQvF2= M1XsblczyqCq NGKxR2tKSzVyPUCuO|U1yqEQvF5CpC=> MUKyOVAxQDlyMB?=
SK-N-AS NGrwU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2wMVExKM7:TR?= NHLVT2Y4OsLiaB?= NXXFcnRrUUN3ME2xMlcyOsLizszNxsA> MonMNlUxODh7MEC=
SK-N-DZ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ZNE0yOCEQvF2= MoDQO|LDqGh? MXrJR|UxRTVwNEi1xsDPxE1? M1LKPFI2ODB6OUCw
HepG2 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuyflE1QMLiaB?= MmnhSG1UV8Li NUHWNFh[UUN3ME2xN{43PcLiwsJCpFAvQTMEoN88US=> NFnIeo0zPDl7NkGzOi=>
A549 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW0SYtkPDkEoHi= MX7EUXNQyqB? MkLtTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= MYiyOFk6PjF|Nh?=
MCF7 NVjSO|kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ROFjDqGh? Mnm1SG1UV8Li M2\o[GlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN NYjsVHIyOjR7OU[xN|Y>
HL-60  MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTDbWtRPzMEoHi= MUfJR|UxRTBwMUNihKXPxE1? MUCyOFk6OzBzNB?=
HL-60[R] NFTQ[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHlVpQ4OsLiaB?= NXjPfYN2UUN3ME2zMlEz6oDHzszN MonyNlQ6QTNyMUS=
MIAPACA M4m4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPPWGhCT0l3ME2xMlMhyrFiMD6wN{DPxE1? MnXYNlQ6PTN6MkG=
MCF-7 NFrjfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\5cWdKPTB;MD6yOUDDuSByLkGg{txO NIjkUVAzPDl3M{iyNS=>
HeLa Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPHTVUxRTBwNkSgxtEhOC52IN88US=> NInsfWUzPDl3M{iyNS=>
MO59K  NFvDTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jUTlch\A>? MXHJR|UxRTBwMUhihKXPxE1? NHrIbYkzPDl3M{W2NS=>
MO59J NV;NcZR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrnZ|A4KGR? Mn[wTWM2OD1yLkJihKXPxE1? MVyyOFk2OzV4MR?=
ME 180 NIHENXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7aOFjDqGkEoB?= MmTRTWM2OD16LkpCpOKyyqByLkRihKXPxE1? NV\SfFA5OjR7NUOwNlc>
MCF-7 NESzb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X5[lQ5yqCqwrC= M4HWd2lEPTB;MkOuPUDDuSByLkRihKXPxE1? MYCyOFk2OzB{Nx?=
HeLa Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ZVlFMPDkEoHlCpC=> MnHhTWM2OD12LkexJOKyKDFwNPMAie69VQ>? NYnpW4s5OjR7NUOwNlc>
MDA-MB-453 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu0POKhcMLi MoXwTWM2OD1zMj61JOKyKDBwOEZihKXPxE1? Mn7MNlQ6PTNyMke=
MDA-MB-231 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvwWHlkPDkEoHlCpC=> M{mxTWlEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= Ml3VNlQ6PTNyMke=
PC-3 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO0POKhcMLi MVHJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? M1\mS|I1QTV|MEK3
HT-29 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL3Z|k1QMLiaNMg MlOwTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP NHLPb3QzPDl3M{CyOy=>
BGC-823 M2L2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK0POKhcMLi MoTQTWM2OD12Mz63OEDDuSB3LkGz5qCG|ryP MVOyOFc6Ozh5Nx?=
HeLa MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi0POKhcMLi MUHJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= NXvZc2Z1OjR5OUO4O|c>
A549 NI\4RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK0POKhcMLi MlflTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= MV:yOFc6Ozh5Nx?=
HK-2 NHGwR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf1cW9PPDkEoHlCpC=> MlTVTWM2OD17LkG3JOKyKDFwNUlihKXPxE1? M2TCWVI1Pzl|OEe3

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID